849 Mitten Road, #105
Burlingame, CA 94010
SUMO Biosciences is developing novel anti-cancer therapeutics by targeting ubiquitin-like modifications. The current focus is on protein modifications by the small ubiquitin-like modifiers (SUMO), because it is a target for inhibiting the c-Myc oncogene that contributes to up to 70% of all human cancers spanning many different types. We have performed proof of principle studies in mouse models of c-Myc driven lymphoma and solid tumor.